Create Free Account

By creating account you will get access to hot stocks & personalised emails

4Dmedical Ltd

Healthcare AU 4DX

0.455AUD
0.005(1.11%)

Last update at 2024-12-19T05:11:00Z

Day Range

0.430.46
LowHigh

52 Week Range

0.410.83
LowHigh

Fundamentals

  • Previous Close 0.45
  • Market Cap189.17M
  • Volume459723
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-44.74710M
  • Revenue TTM3.75M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 0.68M
  • Diluted EPS TTM-0.1

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -40.39550M -31.13658M -24.54967M -21.40522M -22.79334M
Minority interest - - - - -
Net income -35.97867M -31.45980M -24.59288M -21.42053M -21.97538M
Selling general administrative - 23.15M 19.75M 11.74M 13.90M
Selling and marketing expenses - 1.96M 1.37M 0.96M -
Gross profit -28.37948M 0.25M 0.28M 0.13M -8.13397M
Reconciled depreciation - 2.57M 1.50M 0.74M -
Ebit -48.22324M -31.13007M -36.75057M -18.77782M -15.96203M
Ebitda -44.15845M -28.56474M -35.25486M -18.03634M -15.37738M
Depreciation and amortization 4.06M 2.57M 1.50M 0.74M 0.58M
Non operating income net other - - - - -
Operating income -48.22324M -31.13007M -36.75057M -18.77782M -15.96203M
Other operating expenses 51.98M 45.29M 37.80M 24.56M 17.19M
Interest expense 0.26M 0.00650M 0.18M 2.63M 8.02M
Tax provision - 0.32M 0.04M 0.02M 0.00176M
Interest income - 0.31M 0.09M 2.66M 7.96M
Net interest income - 0.31M -0.08696M -2.65719M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -4.41683M 0.32M 0.04M 0.02M -0.81796M
Total revenue 3.75M 0.28M 1.05M 0.22M 1.23M
Total operating expenses 19.84M 45.25M 37.03M 24.46M 7.83M
Cost of revenue 32.13M 0.03M 0.77M 0.09M 9.37M
Total other income expense net 7.83M 13.56M 12.29M 5.59M -6.83131M
Discontinued operations - - - - -
Net income from continuing ops - -31.45980M -24.59288M -21.42053M -
Net income applicable to common shares - -31.45980M -24.59288M -21.42053M -21.97538M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 120.02M 92.92M 74.31M 92.64M 15.82M
Intangible assets - 5.08M 5.06M 3.89M 3.26M
Earning assets - - - - -
Other current assets 1.56M 1.34M 5.59M 4.39M 0.49M
Total liab 49.09M 21.46M 14.80M 9.28M 27.63M
Total stockholder equity 70.93M 71.46M 59.51M 83.36M -11.80985M
Deferred long term liab - 4.06M 4.08M 3.25M 2.75M
Other current liab 14.84M 11.97M 6.65M 7.00M 7.56M
Common stock 218.43M 184.36M 141.72M 141.59M 18.93M
Capital stock - 184.36M 141.72M 141.59M -
Retained earnings -152.03725M -116.05858M -84.59878M -60.00590M -38.58537M
Other liab - 0.19M 0.10M 0.15M 0.06M
Good will - - - - -
Other assets - 4.11M 4.12M 3.34M 2.86M
Cash 30.61M 69.58M 51.11M 80.88M 8.43M
Cash and equivalents - - - - -
Total current liabilities 21.89M 17.07M 9.56M 8.17M 26.96M
Current deferred revenue 1.01M - 6.45M 6.03M -
Net debt -25.48554M - -44.87536M -79.19125M -
Short term debt 0.94M 0.00000M 1.10M 0.72M 17.05M
Short long term debt - - - - -
Short long term debt total 5.12M - 6.24M 1.69M 0.62M
Other stockholder equity - 3.16M 2.39M 1.77M 7.85M
Property plant equipment - 9.26M 10.35M 2.82M 1.77M
Total current assets 39.05M 78.54M 58.85M 85.85M 10.69M
Long term investments - - - - -
Net tangible assets - 70.44M 58.53M 82.72M -12.32278M
Short term investments - - - - -
Net receivables 5.89M 6.96M 2.15M 0.43M 1.75M
Long term debt - - - - 0.62M
Inventory 0.99M 0.67M 0.00151M 0.15M 0.02M
Accounts payable 5.10M 2.86M 1.81M 0.45M 1.67M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 4.53M - 2.39M 1.77M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 72.17M - 0.04M 0.08M -
Deferred long term asset charges - - - - -
Non current assets total 80.96M 14.38M 15.46M 6.79M -
Capital lease obligations - 5.14M 6.24M 1.69M -
Long term debt total - 4.21M 5.14M 0.97M 0.62M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments - -1.61373M -3.50077M -0.58045M -
Change to liabilities - 7.36M -0.47132M 4.58M 1.44M
Total cashflows from investing activities - -1.61373M -3.50077M -0.58045M -0.78645M
Net borrowings - 0.17M -0.99547M -0.53366M 14.06M
Total cash from financing activities 31.94M 42.73M -0.99547M 87.55M 13.78M
Change to operating activities - -1.67787M -0.37286M 0.04M 1.02M
Net income -35.97867M -31.45980M -24.59288M -21.42053M -21.97538M
Change in cash -38.97023M 18.46M -29.76553M 72.45M 5.34M
Begin period cash flow 69.58M 51.11M 80.88M 8.43M 3.09M
End period cash flow 30.61M 69.58M 51.11M 80.88M 8.43M
Total cash from operating activities -30.86688M -22.65269M -25.26928M -14.52000M -7.65035M
Issuance of capital stock - 45.09M - 96.00M -
Depreciation 4.06M 2.57M 1.50M 0.74M 0.58M
Other cashflows from investing activities - - 0.00000M 0.37M 0.37M
Dividends paid - - - - -
Change to inventory - -0.66350M -0.27314M -0.13733M 0.61M
Change to account receivables - -1.82290M -2.01477M 0.87M 0.47M
Sale purchase of stock - -2.53482M 0.00000M -6.38247M 1.22M
Other cashflows from financing activities -40.04044M 0.17M -0.99547M -2.06620M 17.14M
Change to netincome - 1.44M 0.58M 1.54M 10.76M
Capital expenditures 0.30M 0.73M 3.08M 0.73M 1.16M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - 4.80M -2.75421M 4.62M 2.98M
Stock based compensation - 1.01M 0.61M 1.50M 3.47M
Other non cash items 9.18M 1.44M 0.58M 1.54M 9.78M
Free cash flow -31.16975M -23.38401M -28.34742M -15.24501M -8.80880M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
4DX
4Dmedical Ltd		 0.005 1.11% 0.46 - - 50.39 2.73 55.02 -7.2899
COH
Cochlear Ltd		 -3.32 1.13% 291.11 53.50 45.87 8.50 10.43 8.47 32.70
PNV
Polynovo Ltd		 -0.11 5.19% 2.01 206.00 138.89 13.79 20.21 13.83 352.63
AVH
Avita Therapeutics Inc		 -0.2 5.13% 3.70 - - 9.07 28.09 5.79 -10.0538
EBR
Ebr Systems Inc CDR		 0.12 14.53% 0.98 - - - 6.51 - -3.6785

Reports Covered

Stock Research & News

View All

Profile

4DMedical Limited operates as a medical technology company in the United States and Australia. It engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging. The company also offers X-ray velocimetry lung ventilation analysis software (XV LVAS), a lung airflow imaging software, that provides lung health detail from X-Ray scans; computed tomography lung ventilation analysis software (CT LVAS), an image processing software which operates on CT scans to provide functional lung health detail; XV Scanner, a lung function scanner; and Permetium, a multi-function imaging system for pulmonary investigations. The company was incorporated in 2012 and is based in Carlton, Australia.

4Dmedical Ltd

Melbourne Connect, Carlton, VIC, Australia, 3053

Key Executives

Name Title Year Born
Dr. Andreas Fouras M.A.I.C.D., Ph.D. Founder, MD, CTO, CEO & Exec. Director NA
Mr. John Andrew Livingston BAppSci, GradCertBus, GradDipHSc Exec. Director NA
Mr. Simon Glover Chief Financial Officer NA
Mr. Craige Pendleton-Browne B.Sc., M.B.A. Chief Information Officer NA
Beth Plunkett Company Legal Counsel NA
Mr. Clint Rodgers VP of Marketing & Communications NA
Ms. Rachael Tenkaten Chief of Staff NA
Mr. Paul Cooke B.A. Sr. VP of Strategy & Bus. Devel. NA
Dr. Aidan Jamison B.E., Ph.D. Sr. VP of Engineering NA
Dr. Michael Curtis Ph.D. Chief Software Architect NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.